LOGO
LOGO

Coya Therapeutics - Tackling Neurodegeneration By Enhancing Treg Function

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
brain 27102025 lt

Neurodegenerative diseases affect the brain in ways that can lead to changes in personality, language, and behavior. One such condition is frontotemporal dementia (FTD) caused due to damage to neurons in the frontal and temporal lobes of the brain. Unlike other forms of dementia, FTD often occurs at a younger age, typically between 45 and 64 years, and affects an estimated 30,000 Americans. Symptoms can vary widely, including unusual behaviors, emotional problems, trouble communicating, difficulty with work, or difficulty with walking. Currently, there is no cure for FTD, and no treatments slow or stop the progression of the disease.

The company we are profiling today is Coya Therapeutics Inc. (COYA), which is developing therapies for neurodegenerative diseases, including frontotemporal dementia.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update -June 15 - June 19, 2026

June 19, 2026 16:46 ET
Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.

RELATED NEWS